Agena Bioscience opening office in China, aims to sell spectrometry systems in the country

Agena Bioscience's MassArray system--Courtesy of Agena Bioscience

San Diego's Agena Bioscience opened a subsidiary and office in Shanghai, in hopes of selling additional mass spectrometry systems for high-throughput genetic analysis in the country.

"The Chinese market represents a significant portion of Agena Bioscience's global sales with almost sixty MassARRAY Systems installed to date," said CEO Pete Dansky in a statement. "Direct presence within China will allow us to expand our reach and foster a high degree of engagement with our local customers in that region."

The system has various applications, including the profiling of solid tumors and liquid biopsies, genetic disease testing, pharmacogenetics, agricultural genomics and clinical research.

The more than 350 systems are used in 37 countries across the world.

In addition, the company announced the hiring of Bob Wang as its vice president and general manager of greater China. He was previously the marketing director of diagnostics company Qiagen ($QGEN). He also worked at Hologic ($HOLX), Life Technologies ($LIFE), Applied Biosystems and the Chinese Human Genome Center.

The deal comes on the heels of Ilumina's ($ILMN) move to join forces with China's Burning Rock to create cancer diagnostics geared toward the Chinese market, combining its sequencing prowess with Burning Rock's research know-how to increase its footprint in the country.

And over the next three years, Switzerland's Roche ($RHHBY) will sink 450 million Swiss francs ($470 million) into a manufacturing site at Suzhou Industrial Park in Suzhou, China, addressing an increased demand for diagnostic tests in the Asia-Pacific region and expanding its global footprint.

- read the release

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.